stay tuned:
elixi news from the

PALFORZIA® [defatted powder of Arachis hypogaea L., semen (peanuts)]approved in the EU for the treatment of peanut allergy

PALFORZIA® [defatted powder of Arachis hypogaea L., semen (peanuts)]approved in the EU for the treatment of peanut allergy

PALFORZIA is an oral immunotherapy indicated in patients aged 4 to 17 years, who have a confirmed diagnosis of peanut allergy. PALFORZIA may be continued in patients 18 years and older and must be used in conjunction with a peanut-avoidant diet.

“Today’s news of the EC approval represents the first-ever treatment option approved for peanut allergy in the EU and underscores our vision of providing end-to-end solutions as a driver of wellness and treatment, in the key growth areas of nutrition, metabolism, healthy aging and food allergy,” said Greg Behar, CEO of Nestlé Health Science.

Food allergies affect around 17 million people across Europe, with peanut allergy being one of the most common of those. In fact, peanut allergy doubled among children between 2005 and 2015, and the number of hospital admissions due to severe allergic reactions increased seven-fold.1 Severe reactions combined with the difficulty of avoiding peanut protein create an urgent need for treatment.

Andrew Oxtoby, President and CEO of Aimmune Therapeutics, said, “Now we turn our efforts toward working with health authorities to ensure access to this first-of-kind treatment for those children with peanut allergy for whom our product is appropriate as we prepare to launch in Germany and the UK in May 2021.”


Share this article

Pin it

SEE Also

we are specialized in the procurement and distribution of pharmaceutical products, medical devices all over the world

Stay Tuned

Subscribe to our newsletter


    Elixi International SA
    Vicolo Oldelli 12
    6830 Chiasso (TI)


    Tel.  +41 (0)91 6822040


    Elixi Europe Srl
    Via Uberti 6
    21100 Varese (VA)


    Tel.  +41 (0)91 6822040


    Elixi Pharma pte. ltd.
    16 Raffles quay #33-03
    Hong Leong building


    Tel.  +41 (0)91 6822040

    ELIXI International SA

    Copyright 2023 ELIXI International SA.   |   All Rights Reserved   |   Privacy Policy   |   Cookie Policy